Alterations of procalcitonin and interleukin 6 after cardiopulmonary bypass in children with congenital heart disease;Zmiany stȩżeń prokalcytoniny i interleukiny 6 u dzieci z wrodzona̧ waḑ serca podczas zabiegu kardiochirurgicznego i po jego zakończeniu

Polski Merkuriusz Lekarski

Volumn 19, Issue 109, 2005, Pages 20-23

  Paśnik, Jarosław ^a,b   Moll, Jadwiga Anna ^c   Moll, Jacek ^d   Cywińska Bernas, Agnieszka ^a,b   Mazurowski, Wojciech ^a,b   Arendarczyk, Jerzy ^a,b   Sysa, Andrzej ^d   Banasik, Małgorzata ^e   Zeman, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c Klinika Kardiologii   (Poland)

^d Klinika Kardiochirurgii   (Poland)

^e Zaktad Immunologii Klinicznej

Author keywords

Cardiopulmonary bypass; Congenital heart disease; Interleukin 6; Procalcitonin

Indexed keywords

INTERLEUKIN 6; PROCALCITONIN;

ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; EXTRACORPOREAL CIRCULATION; FEMALE; HEART SURGERY; HUMAN; MALE; OUTCOMES RESEARCH; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84860967795     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adamik B., Kubler-Kielb J., Gołçbiowska B. i wsp.: Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: correlation with mortality and postoperative complications. Intensive Care Med., 2000, 26, 1259-1267.
2. Al-Nawas B., Kramer I., Shah P.M.: Procalcitonin in the diagnosis of severe infections. Eur. J. Med. Res., 1996, 1, 331-333.
3. Aouifi A., Piriou V., Bastien O. i wsp.: Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit. Care Med., 2000, 28, 3171-3176.
4. Aouifi A., Piriou V., Blanc P. i wsp.: Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations. Br. J. Anaesth., 1999, 83, 602-607.
5. Arkadek R., Toster E.J., Abellan D.M. i wsp.: Procalcitonin and C-reactive protein kinetics in postoperative pediatric cardiac surgical patients. J. Cardiothorac. Vasc. Anesth., 2004, 18, 160-165.
6. Aydin N.B., Gercekoglu H., Aksu B. i wsp.: Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass. Thorac. Cardiovasc. Surg., 2003, 125, 843-848.
7. Baue A.E., Durham R., Faist E.: Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock, 1998, 10, 79-86.
8. Baykut D., Schulte-Herbruggen J., Krian A.: The value of procalcitonin as an infection marker in cardiac surgery. Eur. J. Med. Res., 2000, 29, 530-536.
9. Beghetti M., Rimensberger P.C., Kalangos A. i wsp.: Kinetics of procalcitonin, interleukin 6 and C-reactive protein after cardiopulmonary-bypass in children. Cardiol. Young, 2003, 13, 161-167.
10. Boeken U., Feindt P., Petzold T. i wsp.: Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin, SIRS, and sepsis. Thorac. Cardiovasc. Surg., 1998, 46, 348-351.
11. Bolger A.P., Genth-Zotz S., Anker S.D.: Heat shock proteins and endotoxin combined as a trigger for inflammatory cytokine release during cardiopulmonary bypass: a possible third way? Circulation, 2002, 106, 49-50.
12. Bone R.C.: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med., 1992, 20, 864-874.
13. Dorge H., Schondube F.A., Dorge P. i wsp.: Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. J. Thorac. Cardiovasc. Surg., 2003, 51, 322-326.
14. Gendrel D., Raymond J., Coste J. i wsp.: Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr. Infect. Dis. J., 1999, 18, 875-881.
15. Hensel M., Volk T., Docke W.D. i wsp.: Hyperprocalcitonemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anestnesiology, 1998, 89, 93-104.
16. Hirai S.: Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass. Ann. Thorac. Cardiovasc. Surg., 2003, 9, 365-370.
17. Holmes J.H., Connolly N.C., Paull D.L. i wsp.: Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm. Res., 2002, 51, 579-586.
18. Hovels-Gurich H.H., Schumacher K., Vazquez-Jimenez J.F. i wsp.: Cytokine balance in infants undergoing cardiac operation. Ann. Thorac. Surg., 2002, 73, 601-608.
19. Hovels-Gurich H.H., Vazquez-Jimenez J.F., Silvestri A. i wsp.: Production of proinflammatory cytokines and myocardial dysfunction after arterial switch operation in neonates with transposition of the great arteries. J. Thorac. Cardiovasc. Surg., 2002, 124, 811-820.
20. Kerbaul F., Guidon C., Lejeune P.J. i wsp.: Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery. J. Cardiothorac. Vasc. Anesth., 2002, 16, 47-53.
21. Lecharny J.B., Khater D., Bronchard R. i wsp.: Hyperprocalcitonemia in patients with perioperative myocardial infarction after cardiac surgery. Crit. Care Med., 2001, 29, 323-325.
22. Loebe M., Locziewski S., Brunkhorst F.M. i wsp.: Procalcitonin in patients undergoing cardiopulmonary bypass in open heart surgery-first results of the procalcitonin in Heart Surgery Study (Prohearts). Intensive Care Med., 2000, 26, (suppl 2), 193-197.
23. McMahon C.K., Klein I., Ojamaa K.: Interleukin-6 and thyroid hormone metabolism in pediatric cardiac surgery patients. Thyroid, 2003, 13, 301-304.
24. Rossi M., Sganga G., Mazzone M. i wsp.: Cardiopulmonary bypass in man: role of the intestine in a self-limiting inflammatory response with demonstrable bacterial translocation. Ann. Thorac. Surg., 2004, 77, 612-618.
25. Sablotzki A., Borgermann J., Baulig W. i wsp.: Lipopolysaccharide-binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac. Cardiovasc. Surg., 2001, 49, 273-238.
26. Tarnok A., Bocsi J., Rossler H. i wsp.: Low degree of activation of circulating neutrophils determined by flow cytometry during cardiac surgery with cardiopulmonary bypass. Cytometry, 2001, 46, 41-49.
27. Tarnok A., Hambsch J., Emmrich F. i wsp.: Complement activation, cytokines and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass. Pediatr. Cardiol., 1999, 20, 113-125.
28. Tsunooka N., Hamada Y., Imagawa H. i wsp.: Ischemia of the intestinal mucosa during cardiopulmonary bypass. J. Artif. Organs, 2003, 6, 149-151.